The number of people suffering from degenerative eye disease increases dramatically with every passing year. The problem is especially acute for the elderly, whose vision is rapidly deteriorating, and patients with diabetes.
In patients such as these, early detection is the key to prolonging sharp, clear vision. In order to monitor changes in their vision, patients should visit the doctor on a regular basis. Unfortunately, in most cases, medical insurance is not sufficient to cover the costs of frequent visits to the doctor, and patients are forced to pay for visits using independent financial means.
Our client spent five years developing an intuitive test that would enable patients to monitor changes in their vision at home.
The Axmor team developed a mobile app for patients based on our client’s test. The app helps to track the progression of eye disease, detecting changes for the purposes of early intervention, and automatically alerting a health care provider in the case of significant deterioration.
Four circles pop up on the screen, one of which is an irregular shape. The patient touches the one that looks different. With each tap of the screen, another four circles appear, and each time the user makes a choice.
As the patient becomes more familiar with the process, it becomes more difficult and adapts to the speed at which the user works through the test.
In order to track any change in vision function, patients need to do the test twice a week.
Every patient’s test results are uploaded to the physician’s portal where they can monitor and track each patient’s performance and disease progression. If a significant deterioration in visual function is suspected, the app will immediately alert a doctor via email or phone. The doctor can then review the case, call the patient in for an assessment and begin a course of treatment.
Each doctor can register new patients, monitor an existing patient’s performance, disease progression and treatment history - all from the physician’s portal.
The mobile app gives physicians access to data relating to patient numbers, the status of active and non-active test participants, and the total number of completed tests.